BRISTOL-MYERS SQUIBB COMPANY (NASDAQ:BMY) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02. Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.
(b) On December 19, 2016, Lamberto Andreotti notified
Bristol-Myers Squibb Company (the Company) that he will not stand
for re-election to the Board of Directors at the 2017 Annual
Meeting of Stockholders, which is expected to be held on May 2,
2017.
Bristol-Myers Squibb Company (the Company) that he will not stand
for re-election to the Board of Directors at the 2017 Annual
Meeting of Stockholders, which is expected to be held on May 2,
2017.
Additionally, on December 21, 2016, the Company announced that
the Board of Directors has elected Giovanni Caforio, M.D., the
Chief Executive Officer of the Company, to become Chairman of the
Board effective May 2, 2017. Dr. Caforio will serve as both
Chairman of the Board and Chief Executive Officer of the Company.
the Board of Directors has elected Giovanni Caforio, M.D., the
Chief Executive Officer of the Company, to become Chairman of the
Board effective May 2, 2017. Dr. Caforio will serve as both
Chairman of the Board and Chief Executive Officer of the Company.
A copy of the press release announcing the retirement of Lamberto
Andreotti from the Board and the election of Giovanni Caforio,
M.D. as Chairman of the Board is attached to this report as
Exhibit 99.1 and incorporated herein by reference.
Andreotti from the Board and the election of Giovanni Caforio,
M.D. as Chairman of the Board is attached to this report as
Exhibit 99.1 and incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
|
99.1
|
Press release dated December 21, 2016
|
About BRISTOL-MYERS SQUIBB COMPANY (NASDAQ:BMY)